Edition:
United States

Cellectis SA (CLLS.OQ)

CLLS.OQ on NASDAQ Stock Exchange Global Market

29.71USD
20 Apr 2018
Change (% chg)

$-0.34 (-1.13%)
Prev Close
$30.05
Open
$30.02
Day's High
$30.02
Day's Low
$29.56
Volume
27,077
Avg. Vol
98,337
52-wk High
$38.85
52-wk Low
$21.31

Select another date:

Wed, Apr 4 2018

BRIEF-Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares

* ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS)

BRIEF-Cellectis Q4 Operating Loss Widens To 27.8 Million Dollars

* REPORTED ON MONDAY Q4 TOTAL REVENUES OF $6.9 MILLION VS $13.0 MILLION YR AGO

France's Cellectis wins U.S patents for gene editing technology

PARIS The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

France's Cellectis wins U.S patents for gene editing technology

PARIS, Feb 13 The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

BRIEF-Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies

* SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

BRIEF-Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer

* CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Select another date: